Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.

The funding of up to £500,000 is provided by LifeArc, a medical research charity, to support the development of Glox’s ...

The FDA placed a clinical hold on two Atara assets, following an inspection at a third-party site that also led to a CRL for ...

The US FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug, to treat chronic hepatitis delta ...

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing for the latter’s ...

Panellists at the World Economic Forum 2025 Davos meeting discussed how artificial intelligence (AI) could help close the gap ...

The Pharmaceutical Technology Excellence Awards winners have been announced! Download our full 50+ page report to find out ...

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

Junshi Biosciences and TopAlliance are set to enter a collaboration with LEO Pharma to distribute and market toripalimab in ...

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...

This rising trend mirrors the evolution of the pharmaceutical industry in terms of investment and utilisation of novel ...